Seven Eight Capital, LP Alnylam Pharmaceuticals, Inc. Transaction History

Seven Eight Capital, LP

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	BUY	$146.51 - $198.2 $3.01 Million - $4.08 Million	20,572 Added 392.82%	25,809 $3.86 Million
Q4 2023 Feb 13, 2024	BUY	$151.41 - $196.57 $792,934 - $1.03 Million	5,237 New	5,237 $1 Million
Q1 2023 May 12, 2023	BUY	$182.66 - $235.53 $423,771 - $546,429	2,320 New	2,320 $464,000
Q3 2022 Nov 10, 2022	BUY	$138.54 - $232.0 $681,755 - $1.14 Million	4,921 New	4,921 $985,000
Q2 2022 Aug 04, 2022	SELL	$120.42 - $169.29 $212,420 - $298,627	-1,764 Closed	0 $0
Q1 2022 May 11, 2022	BUY	$127.18 - $173.91 $224,345 - $306,777	1,764 New	1,764 $288,000
Q4 2019 Feb 13, 2020	SELL	$74.51 - $124.23 $498,024 - $830,353	-6,684 Closed	0 $0
Q3 2019 Nov 14, 2019	BUY	$70.9 - $87.82 $473,895 - $586,988	6,684 New	6,684 $538,000
Q3 2018 Oct 18, 2018	SELL	$87.52 - $122.67 $917,559 - $1.29 Million	-10,484 Closed	0 $0
Q2 2018 Aug 07, 2018	BUY	$88.31 - $107.8 $925,842 - $1.13 Million	10,484 New	10,484 $1.03 Million
Q4 2017 Feb 12, 2018	SELL	$114.49 - $139.98 $2.47 Million - $3.02 Million	-21,584 Closed	0 $0
Q3 2017 Oct 16, 2017	BUY	$72.53 - $118.27 $1.57 Million - $2.55 Million	21,584	21,584 $2.54 Million

647

109M

1.28M

1.22M

Ticker ALNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 123,028,000
Market Cap $33.9B
Description
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...

Get notified when there are updates to the investment portfolio of Seven Eight Capital, LP, based on Form 13F filings with the SEC.

Stay updated on Seven Eight Capital, LP with notifications on news.